TMRW

Based in Australia, TMRW provides personalized health assessment services through advanced biomarker analysis, enabling clients to gain insights into their health and well-being. TMRW, headquartered in Sydney, Australia, was founded in 2025. The company specializes in personalized health assessments, utilizing extensive biomarker testing. In March 2026, TMRW raised USD 7.

00 mn in SEED funding led by Tidal Ventures, with participation from Capital Zed and other investors. This funding round marked their first investment target, with a total amount raised of USD 7. 00 mn. TMRW offers a comprehensive health assessment service focused on personal biology through advanced biomarker analysis.

Their primary product is a membership-based program that includes extensive testing of over 1,700 biomarkers derived from a simple blood sample, allowing clients to gain insights into their health, aging, and overall well-being. This service caters to health-conscious individuals seeking to enhance their health proactively, whether experiencing symptoms or optimizing performance, and operates in markets such as North America, Europe, and Asia. TMRW generates revenue through a subscription-based business model, where clients pay for ongoing access to health assessments and personalized wellness plans. Users engage in two primary testing phases: an at-home finger prick test and an in-clinic blood draw.

Following these assessments, clients receive a detailed analysis and a tailored action plan. This model allows for individual memberships and potential partnerships with health organizations and corporate wellness programs, emphasizing ongoing support tailored to each client's evolving health needs. In March 2026, TMRW will utilize the recently raised USD 7. 00 mn in SEED funding to support its growth and expansion initiatives.

The company plans to introduce new products designed to enhance their health assessment services, although specific product launch dates have not been disclosed. Additionally, TMRW aims to expand into new markets, targeting regions in North America, Europe, and Asia by 2027.